Brown, Jennifer R.

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 2,138

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell

Chronic Lymphocytic Leukemia ResearchCancer Genomics and Diagnostics

Cited by 1,379

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell

Cell death mechanisms and regulationChronic Lymphocytic Leukemia Research

Cited by 361

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Burger, J. A., Landau, D. A., Taylor-Weiner, A., Bozic, I., Zhang, H., Sarosiek, K., Wang, L., Stewart, C., Fan, J., Hoellenriegel, J., et al. (2016) · Nature Communications

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 345

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Bannerji, R., Arnason, J. E., Advani, R. H., Brown, J. R., Allan, J. N., Ansell, S. M., Barnes, J. A., O'Brien, S. M., Chávez, J. C., Duell, J., et al. (2022) · The Lancet Haematology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 254

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Yang, G., Buhrlage, S. J., Tan, L., Liu, X., Chen, J., Xu, L., Tsakmaklis, N., Chen, J. G., Patterson, C. J., Brown, J. R., et al. (2016) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 135

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

Compagno, M., Wang, Q., Pighi, C., Cheong, T.-C., Meng, F.-L., Poggio, T., Yeap, L.-S., Karaca, E., Blasco, R. B., Langellotto, F., et al. (2017) · Nature

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 126

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Naeem, A., Utro, F., Wang, Q., Cha, J., Vihinen, M., Martindale, S., Zhou, Y., Ren, Y., Tyekucheva, S., Kim, A. S., et al. (2023) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 87

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., et al. (2018) · Journal of Clinical Investigation

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 52

Acquired Mutations in Patients with Relapsed/Refractory Cll Who Progressed in the Alpine Study

Brown, J. R., Li, J., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Huang, R., Shi, Y., Idoine, A., et al. (2025) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 14

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Ghosh, N., Lamanna, N., Eyre, T. A., Coombs, C. C., Manzoor, B. S., Brown, J. R., Tuncer, H. H., Ujjani, C. S., Leslie, L. A., Roeker, L. E., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 6